The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis-Reference-Cited by-同舟云学术

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

Published:2016-06 Issue: Volume:249 Page:200-208
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Hennuyer Nathalie,Duplan Isabelle,Paquet Charlotte,Vanhoutte Jonathan,Woitrain Eloise,Touche Véronique,Colin Sophie,Vallez Emmanuelle,Lestavel Sophie,Lefebvre Philippe,Staels Bart

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference43 articles.

1. Inflammation in atherosclerosis;Libby;Arterioscler. Thromb. Vasc. Biol.,2012

2. Macrophages in atherosclerosis: a dynamic balance;Moore;Nat. Rev. Immunol.,2013

3. PPARalpha in atherosclerosis and inflammation;Zandbergen;Biochim. Biophys. Acta,2007

4. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease;Staels;Nat. Clin. Pract. Cardiovasc Med.,2008

5. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction;Tenenbaum;Cardiovasc Diabetol.,2012

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPAR-α Insufficiency Enhances Doxorubicin-Induced Nephropathy in PPAR-α Knockout Mice and a Murine Podocyte Cell Line;Cells;2024-08-28

2. Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease;Gastroenterology Research;2024-08

3. Crosstalk interactions between transcription factors ERRα and PPARα assist PPARα-mediated gene expression;Molecular Metabolism;2024-06

4. Erianin inhibits the progression of triple-negative breast cancer by suppressing SRC-mediated cholesterol metabolism;Cancer Cell International;2024-05-11

5. Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study;JGH Open;2024-04